Literature DB >> 15653031

Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.

Takeshi Aiba1, Wataru Shimizu, Masashi Inagaki, Takashi Noda, Shunichiro Miyoshi, Wei-Guang Ding, Dimitar P Zankov, Futoshi Toyoda, Hiroshi Matsuura, Minoru Horie, Kenji Sunagawa.   

Abstract

OBJECTIVES: We examined the cellular and ionic mechanism for QT prolongation and subsequent Torsade de Pointes (TdP) and the effect of verapamil under conditions mimicking KCNQ1 (I(Ks) gene) defect linked to acquired long QT syndrome (LQTS).
BACKGROUND: Agents with an I(Kr)-blocking effect often induce marked QT prolongation in patients with acquired LQTS. Previous reports demonstrated a relationship between subclinical mutations in cardiac K+ channel genes and a risk of drug-induced TdP.
METHODS: Transmembrane action potentials from epicardial (EPI), midmyocardial (M), and endocardial (ENDO) cells were simultaneously recorded, together with a transmural electrocardiogram, at a basic cycle length of 2,000 ms in arterially perfused feline left ventricular preparations.
RESULTS: The I(Kr) block (E-4031: 1 micromol/l) under control conditions (n = 5) prolonged the QT interval but neither increased transmural dispersion of repolarization (TDR) nor induced arrhythmias. However, the I(Kr) blocker under conditions with I(Ks) suppression by chromanol 293B 10 micromol/l mimicking the KCNQ1 defect (n = 10) preferentially prolonged action potential duration (APD) in EPI rather than M or ENDO, thereby dramatically increasing the QT interval and TDR. Spontaneous or epinephrine-induced early afterdepolarizations (EADs) were observed in EPI, and subsequent TdP occurred only under both I(Ks) and I(Kr) suppression. Verapamil (0.1 to 5.0 micromol/l) dose-dependently abbreviated APD in EPI more than in M and ENDO, thereby significantly decreasing the QT interval, TDR, and suppressing EADs and TdP.
CONCLUSIONS: Subclinical I(Ks) dysfunction could be a risk of drug-induced TdP. Verapamil is effective in decreasing the QT interval and TDR and in suppressing EADs, thus preventing TdP in the model of acquired LQTS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653031     DOI: 10.1016/j.jacc.2004.09.069

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  34 in total

Review 1.  Drug-induced long QT syndrome.

Authors:  Prince Kannankeril; Dan M Roden; Dawood Darbar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.

Authors:  C L Lawrence; M H Bridgland-Taylor; C E Pollard; T G Hammond; J-P Valentin
Journal:  Br J Pharmacol       Date:  2006-10-09       Impact factor: 8.739

3.  Polyunsaturated fatty acid analogs act antiarrhythmically on the cardiac IKs channel.

Authors:  Sara I Liin; Malin Silverå Ejneby; Rene Barro-Soria; Mark Alexander Skarsfeldt; Johan E Larsson; Frida Starck Härlin; Teija Parkkari; Bo Hjorth Bentzen; Nicole Schmitt; H Peter Larsson; Fredrik Elinder
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-21       Impact factor: 11.205

4.  Roles of subcellular Na+ channel distributions in the mechanism of cardiac conduction.

Authors:  Kunichika Tsumoto; Takashi Ashihara; Ryo Haraguchi; Kazuo Nakazawa; Yoshihisa Kurachi
Journal:  Biophys J       Date:  2011-02-02       Impact factor: 4.033

Review 5.  Modulation of the QT interval duration in hypertension with antihypertensive treatment.

Authors:  Jan Klimas; Peter Kruzliak; Simon W Rabkin
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

Review 6.  Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies.

Authors:  Abhishek Jaiswal; Seth Goldbarg
Journal:  Indian Heart J       Date:  2014-01-07

7.  Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.

Authors:  Franck Potet; Amanda N Lorinc; Sebastien Chaigne; Corey R Hopkins; Raghav Venkataraman; Svetlana Z Stepanovic; L Michelle Lewis; Emily Days; Veniamin Y Sidorov; Darren W Engers; Beiyan Zou; David Afshartous; Alfred L George; Courtney M Campbell; Jeffrey R Balser; Min Li; Franz J Baudenbacher; Craig W Lindsley; C David Weaver; Sabina Kupershmidt
Journal:  J Biol Chem       Date:  2012-10-02       Impact factor: 5.157

8.  The Electro-Mechanical window: a risk marker for Torsade de Pointes in a canine model of drug induced arrhythmias.

Authors:  H J van der Linde; B Van Deuren; Y Somers; B Loenders; R Towart; D J Gallacher
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

Review 9.  High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.

Authors:  Juan C Del Álamo; Derek Lemons; Ricardo Serrano; Alex Savchenko; Fabio Cerignoli; Rolf Bodmer; Mark Mercola
Journal:  Biochim Biophys Acta       Date:  2016-03-04

10.  Electrophysiological consequences of dyssynchronous heart failure and its restoration by resynchronization therapy.

Authors:  Takeshi Aiba; Geoffrey G Hesketh; Andreas S Barth; Ting Liu; Samantapudi Daya; Khalid Chakir; Veronica Lea Dimaano; Theodore P Abraham; Brian O'Rourke; Fadi G Akar; David A Kass; Gordon F Tomaselli
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.